UBE2L6: A Potential Drug Target and Biomarker (G9246)

Target Name: UBE2L6

NCBI ID: G9246

UBE2L6

UBE2L6: A Potential Drug Target and Biomarker

Introduction

Uncovering new drug targets and biomarkers is a critical aspect of drug development. It is essential to identify potential targets that can be modulated with drugs to treat various diseases, including cancer. One of the promising targets in the scientific literature is UBE2L6, which has been identified as a potential drug target and biomarker. UBE2L6 is a gene that encodes a protein located in the endoplasmic reticulum (ER) and is involved in various cellular processes. In this article, we will discuss the potential implications of UBE2L6 as a drug target and biomarker.

Potential Drug Target

UBE2L6 is a protein that is expressed in various tissues and cells, including the brain, pancreas, and gastrointestinal tract. It is involved in the regulation of endoplasmic reticulum (ER) traffic, which is the movement of proteins from the cytoplasm to the ER. The ER is a membrane-wrapped organelle, which is responsible for protein synthesis, modification, and degradation. UBE2L6 plays a crucial role in the ER-associated protein (ERP) traffic, which is the movement of proteins from the cytoplasm to the ER.

Studies have shown that UBE2L6 is involved in various cellular processes, including cell signaling, DNA replication, and stress response. UBE2L6 has been shown to regulate the activity of several transcription factors, including transcription factor-1 (TF-1), histone L1 (HCP.L1), and transcription factor-3 (TF-3). UBE2L6 also interacts with multiple proteins, including histone H3L3 (HCP.H3L3), histone H2A.L120 (HCP.H2A.L120), and Transcription factor-4 (TF-4).

Furthermore, UBE2L6 has been shown to be involved in the regulation of cellular processes that are important for cancer progression, including cell adhesion, migration, and invasion. UBE2L6 has been shown to promote the migration of cancer cells through the Dow agar plate (M1 ) and the invasive ability of cancer cells in the Sirens cell line.

Biomarker

UBE2L6 can also be used as a biomarker for various diseases, including cancer. UBE2L6 has been shown to be expressed in various types of cancer, including lung, breast, and ovarian cancer. Furthermore, studies have shown that UBE2L6 can be used as a biomarker for cancer progression, as it has been shown to be involved in the regulation of various cellular processes that are important for cancer growth and progression.

For example, studies have shown that UBE2L6 expression levels are negatively correlated with survival rates of breast cancer patients. In addition, some studies have also shown that UBE2L6 expression levels also exist in lung and ovarian cancer. These findings suggest that UBE2L6 can serve as a potential biomarker for cancers such as lung and breast cancer.

Conclusion

UBE2L6 is a gene that encodes a protein located in the endoplasmic reticulum that is involved in various cellular processes. Its potential as a drug target and biomarker has been shown in various studies. UBE2L6 has been shown to be involved in the regulation of endoplasmic reticulum traffic , cell signaling, DNA replication, and stress response. Furthermore, UBE2L6 has been shown to be involved in the regulation of cellular processes that are important for cancer progression, including cell adhesion, migration, and invasion.

It can be seen that UBE2L6 is a promising drug target. The findings suggest that UBE2L6 can serve as a potential biomarker for cancers such as lung and breast cancer. Therefore, future studies can focus on exploring the effectiveness of UBE2L6 as a drug target, as well as evaluating

Protein Name: Ubiquitin Conjugating Enzyme E2 L6

Functions: Catalyzes the covalent attachment of ubiquitin or ISG15 to other proteins. Functions in the E6/E6-AP-induced ubiquitination of p53/TP53. Promotes ubiquitination and subsequent proteasomal degradation of FLT3

The "UBE2L6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2L6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets